diarrhoeal
diseas
major
public
health
concern
develop
develop
countri
acut
diarrhoea
lead
caus
child
mortal
develop
countri
account
million
death
children
five
year
consequ
econom
impact
diseas
treatment
consider
import
aim
present
paper
provid
updat
aetiolog
epidemiolog
treatment
acut
diarrhoea
children
acut
diarrhoea
defin
product
three
wateri
stool
day
less
day
nonsever
acut
diarrhoea
gastroenterit
origin
stool
contain
visibl
amount
blood
mucu
occur
appropri
diagnosi
dysenteri
requir
specif
manag
world
health
organ
emphasis
import
parent
insight
decid
whether
children
diarrhoea
first
month
life
conspicu
chang
stool
consist
rather
stool
frequenc
must
taken
account
acut
infecti
diarrhoea
result
variou
viral
bacteri
parasit
infect
frequent
infecti
origin
nonetheless
case
caus
agent
detect
rel
contribut
differ
pathogen
may
vari
depend
specif
geograph
locat
season
acut
diarrhoea
predominantli
viral
origin
winter
bacteri
origin
summer
bacteri
pathogen
rel
import
develop
countri
viral
pathogen
rel
import
develop
countri
princip
bacteri
pathogen
respons
infecti
diarrhoea
children
escherichia
coli
respect
viral
pathogen
although
rotavirus
long
consid
princip
pathogen
respons
norovirus
seen
import
emerg
viral
pathogen
thought
lead
caus
nonbacteri
gastroenter
worldwid
signific
caus
mortal
children
rotaviru
infect
account
diarrhoeal
episod
develop
develop
countri
major
caus
acut
diarrhoea
young
children
five
year
age
although
rotaviru
infect
usual
mild
may
lead
pronounc
wateri
stool
loss
may
sometim
lead
sever
dehydr
estim
rotaviru
infect
respons
death
children
year
account
diarrhoearel
death
norovirus
highli
infecti
estim
eighti
percent
nonbacteri
epidem
gastroenter
attribut
norovirus
viral
pathogen
includ
calicivirus
sapovirus
adenovirus
astrovirus
main
bacteri
agent
respons
diarrhoea
includ
campylobact
jejuni
sever
shigella
speci
variou
salmonella
strain
includ
typhi
paratyphi
agent
typhoid
fever
vibrio
cholera
agent
cholera
protozo
pathogen
entamoeba
speci
import
caus
dysenteri
may
difficult
erad
differ
pathogen
may
target
differ
part
gastrointestin
tract
may
influenc
symptomat
manifest
diseas
exampl
e
coli
rotavirus
princip
infect
small
intestin
caus
volumin
wateri
diarrhoea
associ
abdomin
cramp
bloat
ga
weight
loss
shigella
adenovirus
hand
princip
infect
colon
produc
lower
volum
diarrhoea
often
associ
fever
abdomin
pain
infect
larg
intestin
may
frequent
lead
appear
blood
mucu
stool
dysenteri
danger
symptom
infecti
diarrhoea
dehydr
direct
caus
mani
diarrhoeal
death
princip
infant
young
children
extent
dehydr
occur
diarrhoeal
episod
invers
relat
total
bodi
fluid
volum
lowest
children
young
children
especi
first
two
year
life
particularli
risk
acut
diarrhoea
develop
countri
children
also
like
malnourish
aggrav
risk
associ
acut
diarrhoeal
infect
sever
malnutrit
particular
kwashiorkor
may
also
indirect
caus
diarrhoea
children
addit
diarrhoea
especi
persist
sever
day
caus
malnutrit
young
children
due
impair
absorpt
amino
acid
sugar
diarrhoea
increas
loss
water
electrolyt
sodium
chlorid
potassium
bicarbon
liquid
stool
water
electrolyt
also
lost
vomit
sweat
urin
breath
dehydr
occur
loss
replac
adequ
deficit
water
electrolyt
develop
pathophysiolog
perspect
dehydr
aris
interact
infecti
agent
intestin
epithelium
well
underli
cell
present
lamina
propria
sinc
differ
microbi
pathogen
may
caus
diarrhoea
dehydr
diarrhoea
may
aris
varieti
mechan
depend
specif
interact
caus
agent
intestin
epithelium
whatev
initi
caus
dehydr
result
imbal
absorpt
secretori
function
intestin
cellular
level
characteris
inhibit
villou
absorpt
enhanc
crypt
cell
secret
result
mark
loss
water
electrolyt
diarrhoeal
diseas
lead
caus
childhood
morbid
mortal
develop
countri
import
caus
malnutrit
form
childhood
diarrhoea
potenti
life
threaten
childhood
gastroenter
lead
caus
mortal
children
causespecif
death
among
children
five
year
age
year
estim
million
children
five
year
age
die
diarrhoea
incid
mortal
diarrhoeal
diseas
greatest
among
children
younger
one
year
age
declin
thereaft
increment
eight
ten
death
occur
first
two
year
life
accord
recent
whounicef
report
countri
account
almost
death
diarrhoea
among
children
five
year
age
year
figur
child
death
due
diarrhoea
occur
africa
south
asia
incid
acut
gastroenter
children
especi
frequent
area
without
access
clean
water
estim
diarrhoeal
death
worldwid
attribut
unsaf
water
inadequ
sanit
poor
hygien
effort
control
childhood
diarrhoea
result
substanti
declin
child
death
past
three
decad
estim
five
million
death
around
million
children
diarrhoea
remain
second
lead
caus
overal
childhood
mortal
pneumonia
one
major
caus
disabilityadjust
lifeyear
persist
high
rate
morbid
associ
diarrhoea
still
concern
earli
childhood
diarrhoea
may
longterm
effect
growth
cognit
function
develop
countri
one
billion
diarrhoea
episod
occur
everi
year
children
five
year
age
median
episod
diarrhoea
per
childyear
poorest
area
rotaviru
vaccin
introduc
use
recommend
countri
sinc
substanti
declin
morbid
mortal
attribut
rotaviru
allcaus
diarrhoea
seen
countri
vaccin
provid
reduct
number
sever
case
allcaus
diarrhoea
provid
vaccin
appear
substanti
lowmort
countri
instanc
usa
rate
hospitalis
due
acut
diarrhoea
rotaviru
season
per
children
five
year
correspond
decreas
onehalf
twothird
compar
rate
observ
period
prior
vaccin
el
salvador
hospitalis
among
children
five
year
decreas
compar
prevaccin
period
howev
countri
impact
vaccin
hospitalis
rate
report
lower
exampl
mexico
reduct
hospitalis
one
systemat
review
evalu
decreas
incid
case
sever
diarrhoea
vaccin
one
two
avail
vaccin
thu
monoval
rotaviru
vaccin
incid
decreas
lowmort
countri
highmort
countri
vaccin
pentaval
rotaviru
vaccin
incid
reduc
lowmort
countri
highmort
countri
howev
even
though
vaccin
may
modest
effect
highmort
countri
incid
diarrhoea
much
higher
countri
reason
absolut
number
episod
prevent
higher
loperamid
indic
symptomat
treatment
acut
diarrhoea
adult
children
year
age
symptomat
treatment
chronic
diarrhoea
adult
loperamid
synthet
opiat
agonist
figur
activ
receptor
myenter
plexu
larg
intestin
receptor
situat
presynapt
end
parasympathet
cholinerg
innerv
intestin
smooth
muscl
exert
facilitatori
effect
smooth
muscl
contractil
activ
receptor
loperamid
inhibit
releas
acetylcholin
thu
relax
smooth
muscular
tone
gut
wall
physiolog
consequ
enhanc
phasic
colon
segment
inhibit
peristalsi
thu
increas
intestin
transit
time
addit
muscarin
acetylcholin
receptor
secretori
epitheli
cell
gut
wall
mediat
stimul
secret
water
electrolyt
intestin
lumen
parasympathet
activ
inhibit
loperamid
acetylcholin
releas
thu
also
antisecretori
activ
result
loperamid
reduc
daili
faecal
volum
decreas
fluid
electrolyt
loss
increas
stool
viscos
bulk
densiti
contrari
major
opiat
deriv
loperamid
penetr
well
central
nervou
system
reason
present
sed
side
effect
risk
depend
observ
member
class
loperamid
administr
oral
rout
oral
solut
capsul
rapidli
absorb
onset
action
one
hour
maximum
effect
h
administr
absorb
gastrointestin
tract
time
peak
plasma
concentr
hour
oral
solut
hour
capsul
excret
urin
faec
unchang
drug
elimin
halflif
hour
loperamid
metabolis
cytochrom
cyp
system
substrat
isoenzym
number
clinic
trial
vari
qualiti
investig
potenti
antidiarrho
effect
loperamid
metaanalysi
perform
evalu
inform
avail
time
address
efficaci
loperamid
treatment
acut
diarrhoea
children
younger
year
metaanalysi
includ
thirteen
randomis
control
trial
perform
patient
trial
major
methodolog
limit
combin
data
four
highest
qualiti
studi
show
loperamid
significantli
reduc
compar
placebo
risk
persist
diarrhoea
hour
rr
ci
hour
rr
figur
loperamid
also
reduc
significantli
durat
diarrhoea
number
stool
hour
trial
consid
metaanalysi
seriou
advers
event
defin
ileu
lethargi
death
report
children
alloc
loperamid
compar
none
children
alloc
placebo
seriou
advers
event
report
children
age
three
year
author
metaanalysi
conclud
children
three
year
malnourish
moder
sever
dehydr
system
ill
bloodi
diarrhoea
advers
event
outweigh
benefit
children
older
three
year
minim
dehydr
loperamid
may
use
adjunct
oral
rehydr
earli
refeed
addit
number
case
report
paralyt
ileu
children
treat
loperamid
usual
patient
three
year
age
although
loperamid
wide
use
adult
patient
shown
efficaci
paediatr
studi
use
children
discourag
american
academi
pediatr
due
concern
efficaci
safeti
young
children
practic
guidelin
produc
organis
state
loperamid
use
children
twelv
year
age
drug
approv
use
children
countri
although
unit
state
loperamid
approv
fda
use
children
age
two
loperamid
never
given
inflammatori
diseas
suspect
visibl
blood
stool
dysenteri
acut
coliti
racecadotril
figur
indic
symptomat
treatment
acut
diarrhoea
adult
children
racecadotril
prodrug
rapidli
absorb
gut
hydrolys
plasma
activ
metabolit
thiorphan
like
loperamid
racecadotril
interact
opioid
neurotransmitt
system
gut
wall
unlik
loperamid
drug
act
level
opiat
receptor
rather
inhibitor
enzym
neutral
endopeptidas
respons
degrad
endogen
opioid
peptid
met
leuenkephalin
enkephalin
endogen
opioid
neurotransmitt
synthesis
secret
interneuron
enter
nervou
system
act
cholinerg
neuron
enterochromaffin
cell
secretori
epitheli
cell
coordin
gastrointestin
function
wherea
loperamid
activ
princip
subtyp
opiat
receptor
enkephalin
interact
preferenti
opiat
receptor
found
high
densiti
secretori
epitheli
cell
activ
receptor
lead
reduc
secret
water
electrolyt
mediat
decreas
cellular
camp
inhibit
breakdown
enkephalin
thiorphan
facilit
antisecretori
activ
wherea
antidiarrho
effect
loperamid
primarili
mediat
reduc
gastrointestin
motil
action
receptor
racecadotril
essenti
due
antisecretori
effect
mediat
receptor
racecadotril
administr
oral
rout
rapidli
absorb
convert
thiorphan
plasma
maximum
plasma
thiorphan
concentr
achiev
around
one
hour
administr
racecadotril
thiorphan
cross
bloodbrain
barrier
reason
oral
administ
racecadotril
present
minim
central
mediat
opiatelik
effect
thiorphan
metabolis
inact
metabolit
elimin
urin
clinic
trial
racecadotril
evalu
treatment
acut
wateri
diarrhoea
children
number
trial
first
larg
randomis
doubleblind
studi
compar
racecadotril
placebo
adjunct
treatment
or
boy
age
three
present
acut
wateri
diarrhoea
perform
south
america
effect
safeti
racecadotril
use
adjunct
or
treat
acut
gastroenter
children
review
metaanalysi
conduct
szajewska
et
al
princip
outcom
measur
stool
output
consid
object
relev
outcom
measur
clinic
trial
acut
diarrhoea
stool
output
reduc
around
fifti
percent
racecadotril
treatment
group
figur
subsequ
studi
perform
franc
use
similar
design
also
report
similar
reduct
stool
output
number
studi
use
less
rigor
end
point
less
robust
methodolog
gener
report
benefit
racecadotril
compar
placebo
recent
metaanalysi
individu
patient
data
patient
includ
nine
randomis
clinic
trial
analys
compar
efficaci
racecadotril
placebo
adjunct
treatment
or
analysi
demonstr
clinic
relev
benefit
racecadotril
respect
reduc
diarrhoea
durat
figur
stool
output
two
studi
evalu
outcom
stool
number
metaanalysi
identifi
rotaviru
statu
baselin
dehydr
level
import
modul
treatment
respons
found
observ
efficaci
racecadotril
independ
modul
term
safeti
advers
event
specif
associ
racecadotril
identifi
publish
clinic
trial
natur
frequenc
advers
event
patient
treat
racecadotril
similar
observ
placebo
group
frequenc
constip
lower
observ
loperamid
particular
evid
occurr
respiratori
depress
advers
event
frequent
associ
drug
target
opioid
system
final
recent
costutil
analysi
perform
uk
payer
perspect
shown
racecadotril
use
adjuv
therapi
effect
less
costli
compar
or
alon
treatment
children
acut
diarrhoea
probiot
defin
joint
faowho
work
group
food
agricultur
organisationworld
health
organis
live
microorgan
administ
adequ
amount
confer
health
benefit
host
mechan
action
probiot
thought
relat
competit
gut
pathogen
microorgan
nutrient
adhes
site
possibl
secret
probiot
molecul
inhibit
growth
pathogen
microorgan
probiot
microorgan
gener
administ
spore
resist
transit
highli
acid
milieu
stomach
germin
prolifer
less
hostil
environ
intestin
lumen
howev
microorgan
fail
colonis
gastrointestin
tract
persist
disappear
faec
within
day
supplement
ceas
main
therapeut
applic
probiot
treatment
prevent
antibioticassoci
diarrhoea
howev
evid
efficaci
probiot
benefit
observ
strain
specif
dose
depend
metaanalys
attempt
evalu
effect
probiot
treatment
acut
infecti
diarrhoea
conclud
two
probiot
strain
present
efficaci
treatment
acut
diarrhoea
children
statist
signific
effect
moder
clinic
benefit
particular
saccharomyc
boulardii
lactobacillu
gg
shown
efficaci
durat
childhood
diarrhoea
stool
consist
figur
robust
criterion
stool
output
although
major
safeti
issu
gener
associ
probiot
potenti
risk
septicaemia
deep
tissu
infect
microorgan
escap
protect
environ
gut
dissemin
organ
also
theoret
risk
probiot
may
releas
toxin
detriment
host
addit
evid
develop
antibiot
resist
probiot
strain
notabl
lacobacillu
reuteri
enterococcu
faecium
transfer
resist
nativ
gut
flora
intestin
tract
diosmectit
adsorb
clay
miner
indic
treatment
acut
chronic
diarrhoea
natur
multilamellar
clay
belong
dioctahedr
smectit
class
consist
doubl
aluminium
magnesium
silic
arrang
parallel
leaflet
diosmectit
administr
oral
rout
absorb
follow
ingest
act
intestin
lumen
diosmectit
elimin
unchang
directli
faec
within
sixteen
hour
administr
diosmectit
demonstr
sever
pharmacolog
properti
may
benefici
treatment
acut
diarrhoea
firstli
diosmectit
adsorb
bacteri
toxin
bacteria
virus
bile
salt
lysolecithin
includ
enteropathogen
e
coli
rotaviru
coronaviru
well
bacteri
toxin
clostridium
difficil
enterotoxin
b
c
c
perfringen
enterotoxin
one
studi
healthi
volunt
demonstr
diosmectit
could
reduc
product
hydrogen
colon
microbi
ferment
secondli
due
multilay
structur
high
plastic
viscos
diosmectit
possess
power
coat
properti
preserv
integr
mucu
layer
render
intestin
epithelium
resist
attack
endogen
pepsin
bile
salt
exogen
bacteri
toxin
nsaid
alcohol
demonstr
anim
model
human
thirdli
diosmectit
may
affect
intestin
permeabl
electrolyt
flux
perhap
consequ
protect
effect
gastrointestin
epithelium
observ
children
acut
diarrhoea
determin
lactulosemannitol
intestin
permeabl
challeng
test
final
diosmectit
appear
protect
effect
intestin
inflamm
diosmectit
demonstr
suppress
product
cytokin
secretori
epitheli
cell
vitro
attenu
proinflammatori
action
dozen
studi
perform
diosmectit
children
infant
provid
evid
efficaci
medic
treatment
acut
diarrhoea
although
studi
variabl
qualiti
systemat
review
publish
szajewska
et
al
evalu
nine
randomis
control
trial
includ
particip
metaanalysi
studi
carri
children
five
year
major
infant
two
year
main
criterion
metaanalysi
durat
diarrhoea
could
assess
six
includ
studi
enrol
patient
find
six
studi
concur
demonstr
signific
reduct
durat
diarrhoea
patient
treat
diosmectit
figur
standard
mean
differ
diarrhoea
durat
hour
ci
favour
diosmectit
or
group
compar
or
alon
group
differ
statist
signific
p
clinic
relev
metaanalysi
also
evalu
proport
patient
recov
three
five
day
treatment
could
evalu
four
studi
studi
consist
show
higher
recoveri
rate
patient
treat
diosmectit
use
randomeffect
model
rel
chanc
recoveri
ci
day
ci
day
correspond
number
need
treat
day
consid
favour
lack
signific
treatment
effect
day
probabl
account
natur
cours
infecti
diarrhoea
usual
resolv
spontan
time
frame
sinc
public
metaanalysi
two
larg
randomis
placebocontrol
trial
evalu
diosmectit
adjunct
therapi
or
one
conduct
peru
malaysia
two
studi
use
primari
outcom
measur
stool
output
trial
includ
boy
age
month
studi
stool
output
significantli
reduc
diosmectit
group
compar
placebo
group
two
studi
patient
stratifi
rotaviru
infect
statu
greater
cumul
stool
output
observ
rotavirusposit
subgroup
rotavirusneg
subgroup
well
larger
differ
stool
output
diosmectit
placebo
treatment
group
tabl
secondari
analysi
date
pool
two
studi
analysi
varianc
three
factor
rotaviru
statu
studi
treatment
primari
efficaci
outcom
variabl
identifi
signific
effect
rotaviru
statu
p
treatment
p
signific
interact
treatment
rotaviru
statu
p
diarrhoea
durat
secondari
efficaci
criterion
studi
time
recoveri
significantli
shorter
p
logrank
test
diosmectit
treatment
group
compar
placebo
treatment
group
hour
versu
hour
peru
studi
versu
hour
malaysia
studi
differ
two
day
reduct
former
studi
seven
hour
reduct
latter
repres
import
clinic
relev
reduct
diarrhoea
durat
concern
safeti
advers
event
document
systemat
two
recent
randomis
trial
compar
diosmectit
placebo
differ
natur
frequenc
advers
event
diosmectit
placebo
group
observ
consist
safeti
data
report
previou
studi
advers
event
could
imput
diosmectit
emerg
worsen
constip
practic
guidelin
treatment
acut
diarrhoea
children
issu
number
healthcar
organis
indic
guidelin
focu
use
or
cornerston
manag
uncompl
acut
diarrhoea
children
togeth
zinc
supplement
guidelin
consid
antidiarrho
drug
practic
benefit
treatment
condit
recent
recommend
systemat
vaccin
rotaviru
order
reduc
incid
acut
infecti
diarrhoea
children
follow
demonstr
rotaviru
immunis
highli
protect
sever
gastroenter
episod
develop
develop
countri
also
decreas
sever
diarrhoea
lead
less
death
hospit
howev
antirotaviru
immunis
diminish
need
treat
diarrhoeal
episod
occur
regardless
caus
protect
gastroenter
caus
pathogen
practic
guidelin
world
gastroenterolog
organis
wgo
follow
guidelin
consid
antidiarrho
drug
littl
practic
benefit
children
acut
diarrhoea
specifi
loperamid
recommend
children
two
year
age
racecadotril
bismuth
salicyl
reduc
stool
output
children
diarrhoea
may
thu
use
diosmectit
wgo
consid
proof
efficaci
inadequ
note
guidelin
predat
two
larg
randomis
trial
evalu
agent
stool
output
concern
probiot
guidelin
consid
avail
data
support
use
specif
probiot
strain
treatment
prevent
rotaviru
diarrhoea
infant
caution
extrapol
result
probiot
strain
european
societi
paediatr
gastroenterolog
hepatolog
nutrit
espghan
european
societi
paediatr
infecti
diseas
espid
publish
evidencebas
guidelin
manag
acut
gastroenter
children
europ
contrast
wgo
guidelin
guidelin
evalu
pharmacolog
antidiarrho
treatment
although
state
drug
gener
necessari
recommend
relat
antidiarrho
agent
evalu
present
paper
reproduc
tabl
grade
recommend
consid
b
support
level
ii
evid
requir
strong
evid
least
one
properli
design
randomis
control
clinic
trial
appropri
size
acut
diarrhoea
children
major
public
health
burden
associ
consider
health
cost
famili
public
health
organis
program
despit
mark
improv
access
health
servic
diarrhoeal
ill
still
caus
death
children
mainli
develop
countri
also
longterm
consequ
growth
physic
cognit
develop
correct
dehydr
or
mainten
good
nutrit
statu
primari
goal
treatment
adjuv
use
drug
whose
safeti
effect
well
evalu
clearli
demonstr
use
reduc
sever
durat
diarrhoeal
episod
hospit
rate
mortal
appropri
manag
acut
diarrhoea
adequ
valid
treatment
may
help
reduc
health
econom
burden
acut
diarrhoea
children
worldwid
